Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines

References

• NOWELLPCThe minute chromosome (Phl) in chronic granulocytic leukemiaBlut19628 65 6614480647
   PubMedGoogle Scholar
• DaleyGQChronic myeloid leukemia: proving ground for cancer stem cellsCell20041193 314 31615507204
   PubMed Web of Science ®Google Scholar
• BaccaraniMCortesJPaneFChronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNetJ Clin Oncol20092735 6041 605119884523
   PubMed Web of Science ®Google Scholar
• GargRJKantarjianHO’BrienSThe use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-upBlood200911420 4361 436819729517
   PubMed Web of Science ®Google Scholar
• ApperleyJFChronic myeloid leukaemiaThe Lancet20153859976 1447 1459
   PubMed Web of Science ®Google Scholar
• SharpZDBartkeASmithJREvidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf miceJ Gerontol A Biol Sci Med Sci2005603 293 30015860463
   PubMed Web of Science ®Google Scholar
• MorgenszternDMcLeodHLPI3K/Akt/mTOR pathway as a target for cancer therapyAnticancer Drugs2005168 797 80316096426
   PubMed Web of Science ®Google Scholar
• BrownREMorphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patientsExpert Rev Proteomics200523 337 34816000081
   PubMed Web of Science ®Google Scholar
• YipPYPhosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancerTransl Lung Cancer Res201542 165 17625870799
   PubMed Web of Science ®Google Scholar
• LoPiccoloJBlumenthalGMBernsteinWBDennisPATargeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerationsDrug Resist Updat2008111–2 32 5018166498
   PubMed Web of Science ®Google Scholar
• MairaSMStaufferFBrueggenJIdentification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activityMol Cancer Ther200877 1851 186318606717
   PubMed Web of Science ®Google Scholar
• LiCXinPXiaoHZhengYHuangYZhuXThe dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cellsCancer Cell Int201515 6526130968
   PubMed Web of Science ®Google Scholar
• OkabeSTauchiTTanakaYEfficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutationCancer Biol Ther2014152 207 21524100660
   PubMed Web of Science ®Google Scholar
• SunZLiQZhangSNVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylationOnco Targets Ther20158 269 27725674002
   PubMed Web of Science ®Google Scholar
• KugerSCorekEPolatBKammererUFlentjeMDjuzenovaCSNovel PI3K and mTOR inhibitor NVP-BEZ235 radiosensitizes breast cancer cell lines under normoxic and hypoxic conditionsBreast Cancer (Auckl)20148 39 4924678241
   PubMedGoogle Scholar
• IssaAGillJWHeidemanMRCombinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer modelsBreast Cancer Res2013151 R823343422
   PubMed Web of Science ®Google Scholar
• SchnellCRStaufferFAllegriniPREffects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imagingCancer Res20086816 6598 660718701483
   PubMed Web of Science ®Google Scholar
• SerraVMarkmanBScaltritiMNVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutationsCancer Res20086819 8022 803018829560
   PubMed Web of Science ®Google Scholar
• EngelmanJAChenLTanXEffective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNat Med20081412 1351 135619029981
   PubMed Web of Science ®Google Scholar
• SillaberCMayerhoferMBohmAEvaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemiaEur J Clin Invest2008381 43 5218173550
   PubMed Web of Science ®Google Scholar
• LiJXueLHaoHLiRLuoJRapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathwayTumour Biol2014357 6467 647424682932
   PubMedGoogle Scholar
• PellicanoFScottMTHelgasonGVThe antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factorsStem Cells2014329 2324 233724806995
   PubMed Web of Science ®Google Scholar
• WohrleFUHalbachSAumannKGab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitorsLeukemia2013271 118 12922858987
   PubMed Web of Science ®Google Scholar
• SeitzCHugleMCristofanonSTchoghandjianAFuldaSThe dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talkInt J Cancer201313211 2682 269323151917
   PubMed Web of Science ®Google Scholar
• CernigliaGJKararJTyagiSInhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235Mol Pharmacol2012826 1230 124022989521
   PubMed Web of Science ®Google Scholar
• LiuTJKoulDLaFortuneTNVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomasMol Cancer Ther200988 2204 221019671762
   PubMed Web of Science ®Google Scholar
• ShenSKeppOKroemerGThe end of autophagic cell death?Autophagy201281 1 322082964
   PubMed Web of Science ®Google Scholar
• ClarkePGHPuyalJAutophagic cell death existsAutophagy201286 867 86922652592
   PubMed Web of Science ®Google Scholar
• SinclairALatifALHolyoakeTLTargeting survival pathways in chronic myeloid leukaemia stem cellsBr J Pharmacol20131698 1693 170723517124
   PubMed Web of Science ®Google Scholar
• FenouilleNPuissantADufiesMPersistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARCCancer Res20107023 9659 967021098700
   PubMed Web of Science ®Google Scholar
• CrowderRJPhommalyCTaoYPIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancerCancer Res2009699 3955 396219366795
   PubMed Web of Science ®Google Scholar
• McMillinDWOoiMDelmoreJAntimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235Cancer Res20096914 5835 584219584292
   PubMed Web of Science ®Google Scholar